The value of progression-free survival to patients with advanced-stage cancer.
about
Targeted drugs and Psycho-oncological intervention for breast cancer patientsAnti-angiogenesis in prostate cancer: knocked down but not outIs progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol.Population-based trends in systemic therapy use and cost for cancer patients in the last year of life.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.Design Issues in Randomized Clinical Trials of Maintenance Therapies.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedPatient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study.RNAi-mediated downregulation of DNA binding protein A inhibits tumorigenesis in colorectal cancer.Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis.A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration.Palliative medicine update: a multidisciplinary approach.New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.MABp1 for the treatment of colorectal cancer.Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.A critical review on ramucirumab in the treatment of advanced urothelial cancer.The longitudinal relationship between quality of life and survival in advanced stage cancer.Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy.
P2860
Q26748919-1F9B6C38-212F-4E97-A0D3-A461996570EFQ26851183-F2E7958F-2F21-4F5C-8B74-D9DB10BD9EA6Q34439059-2DB25E7D-947A-48CD-9D5B-76271F1D85ABQ35223735-5EF4D0AB-1470-4050-8168-3B7DBD0FC255Q35878603-F7028554-7F54-4B7B-B16C-7172F84324CCQ36122332-F69ABC17-6FD2-42F4-9230-25BE0CCE740CQ36658837-7E5CB615-B375-4D8C-9724-8F266FD011C7Q36680034-3C57F32D-D63B-48CF-941A-3337F744C71FQ36848078-698C24A4-F6B8-496E-99CF-9A96B73CCD46Q36871673-64AD65EE-F58B-432B-85B4-A0B49ADC4D31Q36889650-9AC8C36C-3E5C-41FA-B8D5-7FD0F5A918B8Q36924787-EE79E725-3DA7-4A8C-83B6-2A1CA73E7205Q37187537-79120464-08EB-422F-BB5F-95A684ABF2BCQ37493916-B7F7EC1B-7A02-4BB0-9A5B-7304435F9A0CQ37510005-F1556588-AED9-4CB0-9C96-FEACB3A38F2EQ38067510-3E1B3B70-6ABE-4D58-9005-19B3542746E2Q38162911-918886F6-3D4E-4E94-AAD7-B7C6E86619EEQ38686881-B25B8B93-3E04-4B55-BA4D-C092D6080FA8Q38756061-07061041-41CF-4A3A-8A8D-03DBB6DA104BQ38822094-978F4477-BCA4-4487-9808-4E7CA7B279D5Q39628955-7A602BCE-A5D6-4F05-A4D6-65C91FF1B6DBQ42921489-2D038788-E591-4D9A-8AF5-FF7F27BCF9DDQ47787312-63E35F6B-EED9-425D-8641-EF0DE7FDFA5EQ48038841-62244720-5E80-42B1-BCD0-6F2CC3F8A33BQ50859956-E5F68F69-ACBA-46A1-BCBC-E71D9824AC73
P2860
The value of progression-free survival to patients with advanced-stage cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The value of progression-free survival to patients with advanced-stage cancer.
@en
The value of progression-free survival to patients with advanced-stage cancer.
@nl
type
label
The value of progression-free survival to patients with advanced-stage cancer.
@en
The value of progression-free survival to patients with advanced-stage cancer.
@nl
prefLabel
The value of progression-free survival to patients with advanced-stage cancer.
@en
The value of progression-free survival to patients with advanced-stage cancer.
@nl
P1476
The value of progression-free survival to patients with advanced-stage cancer.
@en
P2093
Anne Fleissig
P356
10.1038/NRCLINONC.2011.156
P407
P577
2011-10-18T00:00:00Z